- Datum25.09.2023
- Uhrzeit18:30 - 19:30 Uhr
- Veranstalter
LYNX
Du willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Erhalte jetzt Zugriff auf konkrete Trading- und Investmentideen Deiner stock3-Experten mit stock3 Trademate.
ROYALTY PHARMA PLC Reg.Ord.Cl.A Shares DL-,0001 Kurse
Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
---|---|---|---|---|---|---|
VK | ||||||
VK | ||||||
VK |
Passende Produkte
Wertentwicklung (Nasdaq)
Wikifolio
Passender Service zu ROYALTY PHARMA PLC Reg.Ord.Cl.A Shares DL-,0001
Webinar zu ROYALTY PHARMA PLC Reg.Ord.Cl.A Shares DL-,0001
Kursinformationen (Nasdaq)
- Tagestief / Hoch-
- 52W-Tief / Hoch25,920-44,470
- Jahrestief / Hoch25,920-39,920
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von ROYALTY PHARMA PLC Reg.Ord.Cl.A Shares DL-,0001
Termine von ROYALTY PHARMA PLC Reg.Ord.Cl.A Shares DL-,0001
Beschreibung
Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
Pivot-Points (Nasdaq)
- Pivot-HBOP - R328,530 $
- Pivot-Resist - R227,940 $
- Pivot-High - R127,100 $
- Pivotpunkt26,510 $
- Pivot-Low - S125,670 $
- Pivot-Support - S225,080 $
- Pivot-LBOP - S324,240 $